Accelerating Therapeutic Development
We accelerate therapeutic development by anchoring every decision in real patient biology captured through deep proteomics and translated via machine learning. By integrating our proprietary clinical data and empirical models, we identify the right therapies for the right patients earlier, enabling more efficient trials and dramatically increasing the odds of clinical success
• We start with assets that are already clinically de-risked, advancing post–Phase I programs with known safety profiles to accelerate time to proof of concept.
• Our platform integrates proteomics, And functional testing perturbations across biological pathways, and machine learning to map molecular signatures to therapeutic response, enabling precise patient selection from day one.
• This approach shortens development timelines by 15–20% and improves trial design, leading to a 5x increase in the likelihood of regulatory success compared to industry benchmarks.
Whether deployed internally or through strategic partnerships, our platform turns molecular complexity into clinical clarity.
Therapeutic Pathways
Our core strength lies in moving beyond simple genomic correlations to capture the dynamic reality of disease and treatment response at the functional level. Deep proteomics, measuring thousands of proteins, their post-translational modifications, and interaction networks, provides a high-resolution snapshot of the disease state and the precise effect of an investigational drug. This data powers our empirical models to perform in silico clinical trials before patient enrollment begins. By simulating how specific proteomic signatures respond to the drug, we can refine dosing strategies, identify potential combination therapies, and, critically, confirm the biological mechanism of action in a patient-relevant context. This functional validation ensures that when an asset enters a Phase II trial, we are testing a highly credible hypothesis on a biologically validated subpopulation, thus minimizing the expensive risk associated with broad, unguided patient recruitment.
Translating Molecular Clarity into Clinical Value
The result of this integrated approach is a pipeline built on de-risked assets and optimized clinical programs. The molecular signatures identified by our platform serve as robust, verifiable biomarkers for patient stratification, turning heterogeneous patient populations into distinct, treatable cohorts. For internal assets, this precision dramatically shortens the path to Proof-of-Concept and reduces the required trial size. For partners, our platform acts as an essential diagnostic layer, transforming stalled or suboptimally performing Phase II assets into potential breakthroughs by rescuing them with a targeted clinical strategy. Ultimately, this focus on real-world, functional biology and predictive modeling doesn't just improve statistics. It ensures that promising therapies reach the patients who stand to benefit most, creating significant clinical and economic value through dramatically increased regulatory and commercial success rates.